Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (531-540 of 557) with videos related to

Pageof 56
Sort By:
European Journal of Heart Failure|February 20, 2021
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyKaren Sliwa, Peter van der Meer, Mark C Petrie, et al.
Cardiovascular Research|June 16, 2021
Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct sizeWeihong He, Charlotte S McCarroll, Katrin Nather, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
JAMA|January 9, 2019
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialPeter J McCartney, Hany Eteiba, Annette M Maznyczka, et al.
European Journal of Heart Failure|July 24, 2025
Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failureRoss T Campbell, Mark C Petrie, Kieran F Docherty, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
Lancet (London, England)|June 24, 2026
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a studyLars H Lund, Arantxa Barandiarán Aizpurua, Entela Bollano, et al.
Pageof 56

Showing results (531-540 of 557) with videos related to

Sort By:
Pageof 56
European Journal of Heart Failure|February 20, 2021
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyKaren Sliwa, Peter van der Meer, Mark C Petrie, et al.
Cardiovascular Research|June 16, 2021
Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct sizeWeihong He, Charlotte S McCarroll, Katrin Nather, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
JAMA|January 9, 2019
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialPeter J McCartney, Hany Eteiba, Annette M Maznyczka, et al.
European Journal of Heart Failure|July 24, 2025
Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failureRoss T Campbell, Mark C Petrie, Kieran F Docherty, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
Lancet (London, England)|June 24, 2026
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a studyLars H Lund, Arantxa Barandiarán Aizpurua, Entela Bollano, et al.
Pageof 56